MedPath

Impact of Antioxidant Treatment on DNA Fragmentation Index

Not Applicable
Completed
Conditions
Male Infertility
Interventions
Dietary Supplement: Androferti
Dietary Supplement: Placebo
Registration Number
NCT03466229
Lead Sponsor
Region Skane
Brief Summary

Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.

Detailed Description

In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant.

Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities.

Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient \~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis.

The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome.

Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (\>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting.

The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options .

The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
79
Inclusion Criteria
  1. Referred due to infertility
  2. Age: 18-50 years,
  3. Non-smoking,
  4. Sperm DNA Fragmentation Index >25%
Exclusion Criteria
  1. Body mass index (BMI) ≥30,
  2. FSH outside the normal range of 2-8 IU/L,g)
  3. LH outside the normal range of 2-10 IU/L,
  4. T < 10nmol/L
  5. Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
  6. History of anabolic steroids use,
  7. Taking antioxidant supplementation the last six months.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AntioxidantAndrofertiAndroferti - 1 twice per day
PlaceboPlaceboPlacebo - 1 twice per day
Primary Outcome Measures
NameTimeMethod
DFI_3Change in DNA Fragmentation Index from Baseline to 3 months

3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin

DFI_6Change in DNA Fragmentation Index from Baseline to 6 months

6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay

Secondary Outcome Measures
NameTimeMethod
Motility_6Change in sperm motility from baseline to 6 months in %

Change sperm motility 6 months

Motility_3Change in sperm motility from baseline to 3 months in %

Change sperm motility 3 months

Morphology_3Change in sperm morphology from baseline to 3 months in %

Change sperm morphology 3 months

Concentration_6Change in sperm concentration from baseline to 6 months in millions/mL

Change sperm concentration 6 months

Morphology_6Change in sperm morphology from baseline to 6 months in %

Change sperm morphology 6 months

Concentration_3Change in sperm concentration from baseline to 3 months in millions/mL

Change sperm concentration 3 months

© Copyright 2025. All Rights Reserved by MedPath